Article Details
Retrieved on: 2024-04-21 16:19:44
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses BrandShield's efforts in combating the sale of counterfeit GLP-1 class drugs in global markets, a concern heightened by their popularity in treating diabetes and aiding weight loss. Key figures like CEO Yoav Keren highlight the dangers posed by counterfeit peptide therapeutics.
Article found on: en.wenews.pk
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here